NEW YORK, NY / ACCESSWIRE / September 29, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Abbott Laboratories (“Abbott Laboratories” or the “Company”) (NYSE:ABT) and is reminding investors of the October 31, 2022 deadline to exercise the role to seek the lead plaintiff in a federal securities class action lawsuit filed against the company.

If you lost more than $100,000 between February 19, 2021 and June 8, 2022 investing in Abbott Laboratories stock or options and discuss your legal rights, call Faruqi & Faruqi Partner Josh Wilson direct at 877-247-4292 or 212-983-9330 (ext. 1310). You can also click here for more information:

Faruqi & Faruqi, LLP, Thursday, September 29, 2022, press release image

There are no costs or obligations for you.

Faruqi & Faruqi is a leading national minority and women-owned securities firm with offices in New York, Pennsylvania, California and Georgia.

Abbott is a medical technology and healthcare company that offers a wide range of products, including various forms of infant formula, sold under the Similac, Alimentum and EleCare brand names. By early 2022, Abbott was responsible for the production of 40 percent of infant formula in the United States. Of that amount, nearly half was manufactured at the Company’s Sturgis, Michigan manufacturing facility (“Sturgis”), meaning that Abbott’s Sturgis facility fed approximately one in six formula-fed babies in the United States.

The Complaint alleges that throughout the Class Period, the Defendants made numerous materially false and misleading statements and omissions regarding conditions at the Company’s facility in made Sturgis. In particular, the defendants have repeatedly touted to investors the safety and salability of Abbott’s infant formula brands and their contribution to the company’s sales and earnings growth.

In truth, Abbott’s facility at Sturgis was in flagrante delicto…